

# CARDIAC BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS



**BIO128B**  
**June 2016**

Anuj Pathak  
***Project Analyst***

ISBN: 1-62296-308-3



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

| TOPIC   | PAGE NO. |
|---|----------|
| CHAPTER 1 INTRODUCTION  | 2        |
| STUDY GOALS AND OBJECTIVES  | 2        |
| REASONS FOR DOING THE STUDY   | 2        |
| SCOPE OF REPORT   | 2        |
| INTENDED AUDIENCE   | 3        |
| METHODOLOGY AND INFORMATION SOURCES   | 4        |
| ANALYST'S CREDENTIALS   | 4        |
| RELATED BCC RESEARCH REPORTS  | 5        |
| BCC RESEARCH WEBSITE  | 5        |
| DISCLAIMER  | 5        |
| CHAPTER 2 SUMMARY   | 7        |
| <i>SUMMARY TABLE GLOBAL CARDIAC BIOMARKER MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>  | 8        |
| <i>SUMMARY FIGURE GLOBAL CARDIAC BIOMARKER MARKET BY REGION, 2014-2020 (\$ MILLIONS)</i>    | 8        |
| CHAPTER 3 OVERVIEW  | 11       |
| MAJOR TRENDS IN THE CARDIAC BIOMARKERS MARKET   | 11       |
| DEVELOPMENT OF POINT-OF-CARE BIOMARKERS MARKET  | 11       |
| IMPROVED CLINICAL AND ANALYTICAL SENSITIVITY  | 11       |
| CHINA TO BE THE LEADING FORCE IN THE ASIAN MARKET   | 11       |
| <i>FIGURE 1 NUMBER OF PATENTS BY COUNTRY, IT* AND HEALTHCARE, 2013 (NO. OF PATENTS)</i>     | 11       |
| GLOBAL INCREASE IN LIFESTYLE-ORIENTED DISEASES AND FATALITIES                               | 12       |
| PATENT TRENDS   | 13       |
| Cardiac Biomarkers Patent by Region   | 13       |
| <i>FIGURE 2 NUMBER OF CARDIAC BIOMARKER PATENTS BY REGION*, 2011-2015 (NO. OF PATENTS)</i>  | 13       |
| Cardiac Biomarkers by Stakeholders  | 14       |
| <i>FIGURE 3 SHARES OF STAKEHOLDERS IN CARDIAC BIOMARKERS PATENTS, 2011-2015 (NO./%)</i>     | 14       |
| Patents by Assignee   | 15       |
| <i>FIGURE 4 NUMBER OF CARDIAC BIOMARKER PATENTS BY ASSIGNEE, 2011-2015 (NO. OF PATENTS)</i> | 15       |
| STRATEGIC TRENDS  | 16       |
| <i>FIGURE 5 TOP STRATEGIES, 2011-2015 (NUMBER)</i>  | 17       |
| TYPE OF BIOMARKERS  | 18       |
| PREDICTIVE  | 18       |
| DIAGNOSTIC  | 19       |
| GOLD STANDARD OF CARDIAC BIOMARKERS   | 19       |
| BIOMARKER DISCOVERY AND VALIDATION  | 19       |
| BIOMARKER CANDIDATE SCREENING   | 19       |
| BIOMARKER CANDIDATE VALIDATION  | 20       |
| ALTERNATIVE MARKETS   | 20       |
| DIAGNOSTIC DEVICES  | 20       |
| CORONARY ANGIOGRAPHY  | 20       |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| <i>TABLE 1 PRICE RANGE OF CORONARY ANGIOGRAPHY/CT ANGIOGRAPHY (\$)</i>                         | 21              |
| MAGNETIC RESONANCE ANGIOGRAM   | 21              |
| X-RAY IMAGING  | 22              |
| ECHOCARDIOGRAPHY   | 22              |
| <i>TABLE 2 DIFFERENT BRANDS AND COST OF ECG MACHINES (\$)</i>                                  | 23              |
| RELATED MARKETS  | 23              |
| PROTEOMICS   | 23              |
| END USERS AND STAKEHOLDERS IN THE BIOMARKER INDUSTRY   | 24              |
| HOSPITALS AND ACADEMIA   | 24              |
| <i>TABLE 3 LEADING HOSPITALS AND INSTITUTES INVOLVED IN BIOMARKER STUDY</i>                    | 25              |
| CONTRACT RESEARCH ORGANIZATIONS  | 25              |
| BIOTECHNOLOGY COMPANIES  | 26              |
| <i>TABLE 4 COMPANIES INVOLVED IN BIOMARKER STUDIES</i>   | 26              |
| EPIDEMIC OF CARDIOVASCULAR DISEASE   | 27              |
| <i>TABLE 5 EPIDEMIC OF CARDIOVASCULAR DISEASES, 2015</i>                                       | 28              |
| RISK FACTORS AND PREVENTION OF CARDIOVASCULAR DISEASE  | 30              |
| <i>FIGURE 6 GLOBAL DISTRIBUTION OF CARDIOVASCULAR DISEASE: DALY, 2004 (PER 100,000 PEOPLE)</i> | 31              |
| <i>FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE TRENDS, 2011-2018 (MILLION CASES)</i>                | 32              |
| CLASSIFICATION OF CARDIOVASCULAR DISEASE   | 32              |
| CORONARY HEART DISEASE   | 33              |
| <i>TABLE 6 DISEASE PROFILE: CORONARY HEART DISEASE</i>   | 34              |
| <i>TABLE 7 HEART DISEASE PERCENTAGE IN DIFFERENT RACES AND ETHNICITIES, 2013 (%)</i>           | 36              |
| ACUTE MYOCARDIAL INFARCTION  | 36              |
| <i>TABLE 8 DISEASE PROFILE: ACUTE MYOCARDIAL INFARCTION</i>                                    | 37              |
| HYPERTENSIVE HEART DISEASE   | 39              |
| <i>TABLE 9 DISEASE PROFILE OF HYPERTENSIVE HEART DISEASE</i>                                   | 40              |
| CEREBROVASCULAR DISEASE  | 42              |
| <i>TABLE 10 DISEASE PROFILE: CEREBROVASCULAR DISEASE</i>                                       | 43              |
| CONGESTIVE HEART FAILURE   | 45              |
| <i>TABLE 11 DISEASE PROFILE: CONGESTIVE HEART FAILURE</i>                                      | 46              |
| PERIPHERAL ARTERIAL DISEASE  | 48              |
| OTHER DISEASES   | 48              |
| <i>TABLE 12 DISEASE PROFILE: HEMORRHAGIC STROKE</i>  | 48              |
| HISTORY AND CURRENT STATE OF HEART DISEASE   | 52              |
| FUTURE DIRECTION OF CARDIAC BIOMARKERS DIAGNOSIS   | 58              |
| BACKGROUND AND CLINICAL VALUE OF CARDIAC BIOMARKERS  | 59              |
| BNP AND NT-PROBNP  | 59              |
| C-REACTIVE PROTEIN   | 60              |
| COPEPTIN   | 61              |
| CREATINE KINASE MB   | 62              |
| D-DIMER  | 63              |
| GALECTIN-3   | 64              |
| HEART FATTY ACID BINDING PROTEIN   | 65              |
| MYOGLOBIN  | 66              |
| <i>TABLE 13 PRODUCT PROFILE: MYOGLOBIN</i>   | 67              |

| <b>TOPIC</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| ST2   | 69              |
| <i>TABLE 14 BIOMARKER PROFILE: ST2</i>  | 70              |
| CARDIAC TROPONIN I/TROPONIN T   | 71              |
| <i>TABLE 15 PRODUCT PROFILE: TROPONIN</i>   | 72              |
| Description of Troponin Biomarkers  | 75              |
| Troponin as the Preferred Biomarker   | 82              |
| <i>FIGURE 8 INTERPRETING ELEVATED LEVELS OF CARDIAC TROPONIN</i>  | 82              |
| CARDIAC BIOMARKERS UNDER DEVELOPMENT  | 84              |
| Choline   | 84              |
| Glial Fibrillary Acidic Protein   | 84              |
| Ischemia-Modified Albumin   | 84              |
| Myeloperoxidase   | 85              |
| S100-Beta   | 85              |
| CLINICAL GUIDELINES OF BIOMARKERS   | 86              |
| TROPONIN/CK-MB/MYOGLOBLIN   | 86              |
| BNP/NT-PROBNP   | 87              |
| COPEPTIN  | 87              |
| GALECTIN-3  | 88              |
| C-REACTIVE PROTEIN  | 89              |
| ST2   | 89              |
| CHAPTER 4 INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS   | 92              |
| INDUSTRY STRUCTURE  | 92              |
| DIAGNOSTIC METHODS  | 92              |
| IMMUNOASSAY   | 92              |
| Radioimmunoassay  | 93              |
| Enzyme-Linked Immunosorbent Assay   | 93              |
| Chemiluminescent Enzyme Immunoassay   | 94              |
| LIGHT SCATTERING  | 95              |
| Turbidimetry  | 95              |
| Nephelometry  | 95              |
| Particle Counting   | 95              |
| New Developments  | 95              |
| LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY   | 96              |
| PATENT ANALYSIS   | 96              |
| NEWLY ISSUED PATENTS  | 96              |
| <i>TABLE 16 PATENT TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2009-2015 (NO. OF PATENTS)</i> | 97              |
| Patents on Assays   | 97              |
| <i>TABLE 17 PATENTS BY BIOMARKER CATEGORY, 2009-2015 (NO./%)</i>  | 97              |
| Patents by Manufacturer/Research Institute  | 97              |
| <i>TABLE 18 PATENTS BY COMPANY, 2009-2015 (NO./%)</i>   | 98              |
| <i>TABLE 19 PATENTS ON CARDIAC BIOMARKER BY ASSIGNEE TYPE (NO./%)</i>   | 98              |
| <i>TABLE 20 PATENT ANALYSIS BY REGION, 2009-2015 (NO./%)</i>  | 99              |
| <i>TABLE 21 U.S. PATENT ANALYSIS, 2009-2015 (NO./%)</i>   | 99              |
| <i>TABLE 22 EUROPEAN PATENT ANALYSIS, 2009-2015 (NO./%)</i>   | 100             |
| <i>TABLE 23 PATENTS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2015</i>                             | 100             |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| NEW PATENT APPLICATIONS  | 102             |
| Patents by Focus   | 102             |
| <i>TABLE 24 PATENT APPLICATION TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, APRIL-JUNE 2015 (NO.)</i> | 103             |
| <i>TABLE 25 EXAMPLES OF PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015</i>  | 103             |
| Patents by Manufacturer/Research Institute   | 105             |
| <i>TABLE 26 PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015 (NO./%)</i>  | 105             |
| COMPETITIVE LANDSCAPE  | 106             |
| <i>FIGURE 9 RECENT KEY STRATEGIES OF CARDIAC BIOMARKER MARKET, 2011-2015 (NO./%)</i>                                     | 106             |
| <i>TABLE 27 PARTNERSHIP AND COLLABORATION, 2011-2015</i>   | 107             |
| <i>FIGURE 10 PARTNERSHIP AND COLLABORATION BY COMPANY,* 2011-2015 (NO./%)</i>  | 110             |
| PRODUCT APPROVALS AND PRODUCT CLEARANCES   | 111             |
| <i>TABLE 28 PRODUCT APPROVALS AND PRODUCT CLEARANCES, 2011-2015</i>  | 111             |
| <i>FIGURE 11 PRODUCT APPROVALS AND PRODUCT CLEARANCES BY COMPANIES, 2011-2015 (NO./%)</i>                                | 112             |
| NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES  | 113             |
| <i>TABLE 29 NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES, 2011-2015</i>   | 114             |
| <i>FIGURE 12 NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES BY COMPANY, 2011-2015 (NO./%)</i>                             | 115             |
| MERGERS AND ACQUISITIONS   | 116             |
| <i>TABLE 30 MERGERS AND ACQUISITIONS, 2011-2015</i>  | 116             |
| <i>FIGURE 13 MERGERS AND ACQUISITIONS BY COMPANY, 2011-2015 (NO./%)</i>  | 117             |
| OTHER STRATEGIES   | 118             |
| <i>TABLE 31 OTHER STRATEGIES, 2011-2015</i>  | 118             |
| GOVERNMENT REGULATION  | 120             |
| U.S. FDA 501K APPROVAL   | 120             |
| Division Acceptance and Review   | 120             |
| Examples of U.S. FDA 501(k) Approval   | 121             |
| CE MARKING IN EUROPE   | 122             |
| Examples of CE Marking in Europe   | 123             |
| OTHER INTERNATIONAL REGULATORY AGENCIES  | 123             |
| TRENDS IN PRICE AND PRICE/PERFORMANCE  | 123             |
| GENERAL TECHNOLOGY ISSUES  | 124             |
| SENSITIVITY AND SPECIFICITY  | 124             |
| POSITIVE AND NEGATIVE PREDICTIVE VALUES  | 125             |
| RECEIVER OPERATOR CHARACTERISTIC CURVES  | 125             |
| <i>FIGURE 14 RECEIVER OPERATOR CHARACTERISTIC CURVES</i>   | 126             |
| CHAPTER 5 SUMMARY OF MARKET BY ASSAYS  | 128             |
| <i>TABLE 32 GLOBAL CARDIAC BIOMARKERS MARKET BY ASSAY CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>                           | 128             |
| CHAPTER 6 MARKET BY INSTRUMENT   | 130             |
| CLINICAL CHEMISTRY ANALYZERS   | 130             |
| FUTURE OF CLINICAL CHEMISTRY ANALYZERS   | 130             |
| POINT-OF-CARE DEVICES  | 131             |
| FUTURE OF POINT-OF-CARE TESTING  | 131             |

| <b>TOPIC</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| MARKET BY INSTRUMENT CATEGORY   | 132             |
| TABLE 33 GLOBAL CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                   | 133             |
| TABLE 34 GLOBAL CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                     | 133             |
| TABLE 35 GLOBAL BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)        | 133             |
| TABLE 36 GLOBAL CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                    | 134             |
| TABLE 37 GLOBAL NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                 | 134             |
| TABLE 38 GLOBAL OTHER BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                   | 134             |
| CHAPTER 7 MARKET BY REGION  | 136             |
| SUMMARY OF MARKET BY REGION   | 136             |
| NORTH AMERICA   | 136             |
| UNITED STATES   | 137             |
| CANADA  | 137             |
| TABLE 39 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)                         | 138             |
| TABLE 40 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)           | 138             |
| TABLE 41 NORTH AMERICA CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)              | 139             |
| TABLE 42 NORTH AMERICA BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS) | 139             |
| TABLE 43 NORTH AMERICA CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)             | 139             |
| TABLE 44 NORTH AMERICA NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)          | 140             |
| TABLE 45 NORTH AMERICA OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)             | 140             |
| EUROPEAN MARKET   | 140             |
| UNITED KINGDOM  | 141             |
| FRANCE  | 142             |
| GERMANY   | 142             |
| TABLE 46 EUROPEAN CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)                              | 143             |
| TABLE 47 EUROPEAN CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                | 143             |
| TABLE 48 EUROPEAN CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                       | 143             |
| TABLE 49 EUROPEAN BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)          | 144             |
| TABLE 50 EUROPEAN CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                      | 144             |
| TABLE 51 EUROPEAN NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)               | 144             |
| TABLE 52 EUROPEAN OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                  | 145             |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| ASIA-PACIFIC MARKET  | 145             |
| INDIA  | 145             |
| CHINA  | 146             |
| Regulations in China   | 146             |
| JAPAN  | 147             |
| Regulations in Japan   | 147             |
| <i>TABLE 53 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)</i>                       | 148             |
| <i>TABLE 54 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>         | 148             |
| <i>TABLE 55 ASIA-PACIFIC CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>               | 149             |
| <i>TABLE 56 ASIA-PACIFIC BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>  | 149             |
| <i>TABLE 57 ASIA-PACIFIC CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>              | 149             |
| <i>TABLE 58 ASI-PACIFIC NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>        | 150             |
| <i>TABLE 59 ASIA-PACIFIC MARKET FOR OTHER BIOMARKERS BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>      | 150             |
| MARKET IN THE REST OF THE WORLD  | 150             |
| <i>TABLE 60 REST OF WORLD CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)</i>                     | 151             |
| <i>TABLE 61 REST OF WORLD CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>       | 151             |
| <i>TABLE 62 REST OF WORLD CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>              | 152             |
| <i>TABLE 63 REST OF WORLD BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i> | 152             |
| <i>TABLE 64 REST OF WORLD CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>             | 152             |
| <i>TABLE 65 REST OF WORLD NEW BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>          | 153             |
| CHAPTER 8 COMPANY PROFILES   | 155             |
| ABBOTT DIAGNOSTICS   | 155             |
| <i>TABLE 66 ABBOTT DIAGNOSTICS: KEY PRODUCTS</i>   | 155             |
| <i>TABLE 67 ABBOTT DIAGNOSTICS: RECENT DEVELOPMENTS</i>  | 155             |
| ALERE INC.   | 156             |
| <i>TABLE 68 ALERE INC.: KEY PRODUCTS</i>   | 157             |
| COMPANY STRATEGY   | 157             |
| <i>TABLE 69 ALERE INC.: RECENT DEVELOPMENTS</i>  | 157             |
| BECKMAN COULTER  | 158             |
| <i>TABLE 70 BECKMAN COULTER: KEY PRODUCTS</i>  | 158             |
| COMPANY STRATEGY   | 159             |
| <i>TABLE 71 BECKMAN COULTER: RECENT DEVELOPMENTS</i>   | 159             |
| BECTON, DICKINSON AND CO.  | 159             |
| <i>TABLE 72 BECTON, DICKINSON AND CO.: KEY PRODUCTS</i>  | 160             |
| COMPANY STRATEGY   | 160             |
| <i>TABLE 73 BECTON, DICKINSON AND CO.: RECENT DEVELOPMENTS</i>   | 160             |

| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| BG MEDICINE INC.   | 161             |
| <i>TABLE 74 BG MEDICINE INC: KEY PRODUCTS</i>                          | 161             |
| <i>TABLE 75 BG MEDICINE INC: RECENT DEVELOPMENTS</i>                   | 161             |
| BIOMERIEUX   | 162             |
| <i>TABLE 76 BIOMERIEUX: KEY PRODUCTS</i>                               | 162             |
| COMPANY STRATEGY   | 163             |
| <i>TABLE 77 BIOMERIEUX: RECENT DEVELOPMENTS</i>                        | 163             |
| BIO-RAD LABORATORIES   | 163             |
| <i>TABLE 78 BIO-RAD LABORATORIES: KEY PRODUCTS</i>                     | 164             |
| <i>TABLE 79 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS</i>              | 164             |
| CISBIO BIOASSAYS   | 164             |
| <i>TABLE 80 CISBIO BIOASSAYS: KEY PRODUCTS</i>                         | 165             |
| COVANCE  | 166             |
| <i>TABLE 81 COVANCE: KEY PRODUCTS</i>                                  | 166             |
| EKF DIAGNOSTICS  | 167             |
| <i>TABLE 82 EKF DIAGNOSTICS: KEY PRODUCTS</i>                          | 167             |
| <i>TABLE 83 EKF DIAGNOSTICS: RECENT DEVELOPMENTS</i>                   | 168             |
| ENZO BIOCHEM INC.  | 168             |
| <i>TABLE 84 ENZO BIOCHEM INC.: KEY PRODUCTS</i>                        | 168             |
| HOLOGIC INC.   | 169             |
| <i>TABLE 85 HOLOGIC INC.: KEY PRODUCTS</i>                             | 169             |
| MESO SCALE DIAGNOSTICS   | 169             |
| <i>TABLE 86 MESO SCALE DIAGNOSTICS: KEY PRODUCTS</i>                   | 170             |
| ORTHO CLINICAL DIAGNOSTICS   | 171             |
| <i>TABLE 87 ORTHO CLINICAL DIAGNOSTICS: KEY PRODUCTS</i>               | 171             |
| <i>TABLE 88 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS</i>        | 171             |
| PACIFIC BIOMARKERS INC.  | 171             |
| <i>TABLE 89 PACIFIC BIOMARKERS INC.: KEY PRODUCTS (CARDIOVASCULAR)</i> | 172             |
| <i>TABLE 90 PACIFIC BIOMARKERS INC.: RECENT DEVELOPMENTS</i>           | 173             |
| PERKIN ELMER INC.  | 173             |
| <i>TABLE 91 PERKIN ELMER INC.: KEY PRODUCTS</i>                        | 173             |
| QIAGEN NV  | 174             |
| <i>TABLE 92 QIAGEN NV: KEY PRODUCTS</i>                                | 174             |
| <i>TABLE 93 QIAGEN NV: RECENT DEVELOPMENTS</i>                         | 175             |
| RADIOMETER MEDICAL   | 175             |
| <i>TABLE 94 RADIOMETER MEDICAL: KEY PRODUCTS</i>                       | 176             |
| <i>TABLE 95 RADIOMETER MEDICAL: RECENT DEVELOPMENTS</i>                | 176             |
| RANDOX LABORATORIES LTD.   | 176             |
| <i>TABLE 96 RANDOX LABORATORIES LTD.: KEY PRODUCTS</i>                 | 177             |
| <i>TABLE 97 RANDOX LABORATORIES LTD.: RECENT DEVELOPMENTS</i>          | 178             |
| RESPONSE BIOMEDICAL CORP.  | 178             |
| <i>TABLE 98 RESPONSE BIOMEDICAL CORP.: KEY PRODUCTS</i>                | 179             |
| <i>TABLE 99 RESPONSE BIOMEDICAL CORP.: RECENT DEVELOPMENTS</i>         | 179             |
| ROCHE HOLDING AG   | 180             |
| <i>TABLE 100 ROCHE HOLDING AG: KEY PRODUCTS</i>                        | 180             |
| <i>TABLE 101 ROCHE HOLDING AG: RECENT DEVELOPMENTS</i>                 | 181             |
| SIGNOSIS INC.  | 182             |



| <b>TOPIC</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| <i>TABLE 102 SIGNOSIS INC.: KEY PRODUCTS</i>                         | 182             |
| SIEMENS HEALTHCARE DIAGNOSTICS                                       | 182             |
| <i>TABLE 103 SIEMENS HEALTHCARE DIAGNOSTICS: KEY PRODUCTS</i>        | 183             |
| <i>TABLE 104 SIEMENS HEALTHCARE DIAGNOSTICS: RECENT DEVELOPMENTS</i> | 183             |
| SINGULEX, INC.   | 184             |
| <i>TABLE 105 SINGULEX, INC.: KEY PRODUCTS</i>                        | 184             |
| <i>TABLE 106 SINGULEX, INC.: RECENT DEVELOPMENTS</i>                 | 185             |
| THERMO FISHER SCIENTIFIC INC.  | 186             |
| <i>TABLE 107 THERMO FISHER SCIENTIFIC INC: KEY PRODUCTS</i>          | 187             |
| <i>TABLE 108 THERMO FISHER SCIENTIFIC INC: RECENT DEVELOPMENTS</i>   | 187             |
| WUXI APTEC   | 188             |
| <i>TABLE 109 WUXI APTEC'S SERVICES</i>                               | 189             |
| <i>TABLE 110 WUXI APTEC: RECENT DEVELOPMENTS</i>                     | 189             |
| POTENTIAL ENTRANTS   | 190             |
| EVOTEC   | 190             |
| JOHNSON & JOHNSON  | 190             |
| MERCK AND CO. INC.   | 191             |
| QUINTILES  | 191             |
|  |                 |
| CHAPTER 9 APPENDIX   | 193             |
| <i>TABLE 111 LIST OF PATENTS, 2006-2015</i>                          | 193             |

**LIST OF TABLES**

| <b>TABLE HEADING</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| SUMMARY TABLE GLOBAL CARDIAC BIOMARKER MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)                               | 8               |
| TABLE 1 PRICE RANGE OF CORONARY ANGIOGRAPHY/CT ANGIOGRAPHY (\$)   | 21              |
| TABLE 2 DIFFERENT BRANDS AND COST OF ECG MACHINES (\$)  | 23              |
| TABLE 3 LEADING HOSPITALS AND INSTITUTES INVOLVED IN BIOMARKER STUDY  | 25              |
| TABLE 4 COMPANIES INVOLVED IN BIOMARKER STUDIES   | 26              |
| TABLE 5 EPIDEMIC OF CARDIOVASCULAR DISEASES, 2015   | 28              |
| TABLE 6 DISEASE PROFILE: CORONARY HEART DISEASE   | 34              |
| TABLE 7 HEART DISEASE PERCENTAGE IN DIFFERENT RACES AND ETHNICITIES, 2013 (%)                                     | 36              |
| TABLE 8 DISEASE PROFILE: ACUTE MYOCARDIAL INFARCTION  | 37              |
| TABLE 9 DISEASE PROFILE OF HYPERTENSIVE HEART DISEASE   | 40              |
| TABLE 10 DISEASE PROFILE: CEREBROVASCULAR DISEASE   | 43              |
| TABLE 11 DISEASE PROFILE: CONGESTIVE HEART FAILURE  | 46              |
| TABLE 12 DISEASE PROFILE: HEMORRHAGIC STROKE  | 48              |
| TABLE 13 PRODUCT PROFILE: MYOGLOBIN   | 67              |
| TABLE 14 BIOMARKER PROFILE: ST2   | 70              |
| TABLE 15 PRODUCT PROFILE: TROPONIN  | 72              |
| TABLE 16 PATENT TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2009-2015 (NO. OF PATENTS)        | 97              |
| TABLE 17 PATENTS BY BIOMARKER CATEGORY, 2009-2015 (NO./%)   | 97              |
| TABLE 18 PATENTS BY COMPANY, 2009-2015 (NO./%)  | 98              |
| TABLE 19 PATENTS ON CARDIAC BIOMARKER BY ASSIGNEE TYPE (NO./%)  | 98              |
| TABLE 20 PATENT ANALYSIS BY REGION, 2009-2015 (NO./%)   | 99              |
| TABLE 21 U.S. PATENT ANALYSIS, 2009-2015 (NO./%)  | 99              |
| TABLE 22 EUROPEAN PATENT ANALYSIS, 2009-2015 (NO./%)  | 100             |
| TABLE 23 PATENTS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2015                                    | 100             |
| TABLE 24 PATENT APPLICATION TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, APRIL-JUNE 2015 (NO.) | 103             |
| TABLE 25 EXAMPLES OF PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015  | 103             |
| TABLE 26 PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015 (NO./%)  | 105             |
| TABLE 27 PARTNERSHIP AND COLLABORATION, 2011-2015   | 107             |
| TABLE 28 PRODUCT APPROVALS AND PRODUCT CLEARANCES, 2011-2015  | 111             |
| TABLE 29 NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES, 2011-2015   | 114             |
| TABLE 30 MERGERS AND ACQUISITIONS, 2011-2015  | 116             |
| TABLE 31 OTHER STRATEGIES, 2011-2015  | 118             |
| TABLE 32 GLOBAL CARDIAC BIOMARKERS MARKET BY ASSAY CATEGORY, THROUGH 2020 (\$ MILLIONS)                           | 128             |
| TABLE 33 GLOBAL CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                       | 133             |
| TABLE 34 GLOBAL CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                         | 133             |
| TABLE 35 GLOBAL BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)            | 133             |
| TABLE 36 GLOBAL CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                        | 134             |
| TABLE 37 GLOBAL NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                     | 134             |

| <b>TABLE HEADING</b>  | <b>PAGE NO.</b> |
|---|-----------------|
| TABLE 38 GLOBAL OTHER BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                   | 134             |
| TABLE 39 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)                         | 138             |
| TABLE 40 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)           | 138             |
| TABLE 41 NORTH AMERICA CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)              | 139             |
| TABLE 42 NORTH AMERICA BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS) | 139             |
| TABLE 43 NORTH AMERICA CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)             | 139             |
| TABLE 44 NORTH AMERICA NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)          | 140             |
| TABLE 45 NORTH AMERICA OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)             | 140             |
| TABLE 46 EUROPEAN CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)                              | 143             |
| TABLE 47 EUROPEAN CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                | 143             |
| TABLE 48 EUROPEAN CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                       | 143             |
| TABLE 49 EUROPEAN BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)          | 144             |
| TABLE 50 EUROPEAN CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                      | 144             |
| TABLE 51 EUROPEAN NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)               | 144             |
| TABLE 52 EUROPEAN OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                  | 145             |
| TABLE 53 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)                           | 148             |
| TABLE 54 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)             | 148             |
| TABLE 55 ASIA-PACIFIC CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                   | 149             |
| TABLE 56 ASIA-PACIFIC BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)      | 149             |
| TABLE 57 ASIA-PACIFIC CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                  | 149             |
| TABLE 58 ASI-PACIFIC NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)            | 150             |
| TABLE 59 ASIA-PACIFIC MARKET FOR OTHER BIOMARKERS BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)          | 150             |
| TABLE 60 REST OF WORLD CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 (\$ MILLIONS)                         | 151             |
| TABLE 61 REST OF WORLD CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)           | 151             |
| TABLE 62 REST OF WORLD CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)                  | 152             |
| TABLE 63 REST OF WORLD BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)     | 152             |

| <b>TABLE HEADING</b>   | <b>PAGE NO.</b> |
|--|-----------------|
| TABLE 64 REST OF WORLD CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS)    | 152             |
| TABLE 65 REST OF WORLD NEW BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 (\$ MILLIONS) | 153             |
| TABLE 66 ABBOTT DIAGNOSTICS: KEY PRODUCTS  | 155             |
| TABLE 67 ABBOTT DIAGNOSTICS: RECENT DEVELOPMENTS   | 155             |
| TABLE 68 ALERE INC.: KEY PRODUCTS  | 157             |
| TABLE 69 ALERE INC.: RECENT DEVELOPMENTS   | 157             |
| TABLE 70 BECKMAN COULTER: KEY PRODUCTS   | 158             |
| TABLE 71 BECKMAN COULTER: RECENT DEVELOPMENTS  | 159             |
| TABLE 72 BECTON, DICKINSON AND CO.: KEY PRODUCTS   | 160             |
| TABLE 73 BECTON, DICKINSON AND CO.: RECENT DEVELOPMENTS  | 160             |
| TABLE 74 BG MEDICINE INC: KEY PRODUCTS   | 161             |
| TABLE 75 BG MEDICINE INC: RECENT DEVELOPMENTS  | 161             |
| TABLE 76 BIOMERIEUX: KEY PRODUCTS  | 162             |
| TABLE 77 BIOMERIEUX: RECENT DEVELOPMENTS   | 163             |
| TABLE 78 BIO-RAD LABORATORIES: KEY PRODUCTS  | 164             |
| TABLE 79 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS   | 164             |
| TABLE 80 CISBIO BIOASSAYS: KEY PRODUCTS  | 165             |
| TABLE 81 COVANCE: KEY PRODUCTS   | 166             |
| TABLE 82 EKF DIAGNOSTICS: KEY PRODUCTS   | 167             |
| TABLE 83 EKF DIAGNOSTICS: RECENT DEVELOPMENTS  | 168             |
| TABLE 84 ENZO BIOCHEM INC.: KEY PRODUCTS   | 168             |
| TABLE 85 HOLOGIC INC.: KEY PRODUCTS  | 169             |
| TABLE 86 MESO SCALE DIAGNOSTICS: KEY PRODUCTS  | 170             |
| TABLE 87 ORTHO CLINICAL DIAGNOSTICS: KEY PRODUCTS  | 171             |
| TABLE 88 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS   | 171             |
| TABLE 89 PACIFIC BIOMARKERS INC.: KEY PRODUCTS (CARDIOVASCULAR)                                  | 172             |
| TABLE 90 PACIFIC BIOMARKERS INC.: RECENT DEVELOPMENTS  | 173             |
| TABLE 91 PERKIN ELMER INC.: KEY PRODUCTS   | 173             |
| TABLE 92 QIAGEN NV: KEY PRODUCTS   | 174             |
| TABLE 93 QIAGEN NV: RECENT DEVELOPMENTS  | 175             |
| TABLE 94 RADIOMETER MEDICAL: KEY PRODUCTS  | 176             |
| TABLE 95 RADIOMETER MEDICAL: RECENT DEVELOPMENTS   | 176             |
| TABLE 96 RANDOX LABORATORIES LTD.: KEY PRODUCTS  | 177             |
| TABLE 97 RANDOX LABORATORIES LTD.: RECENT DEVELOPMENTS   | 178             |
| TABLE 98 RESPONSE BIOMEDICAL CORP.: KEY PRODUCTS   | 179             |
| TABLE 99 RESPONSE BIOMEDICAL CORP.: RECENT DEVELOPMENTS  | 179             |
| TABLE 100 ROCHE HOLDING AG: KEY PRODUCTS   | 180             |
| TABLE 101 ROCHE HOLDING AG: RECENT DEVELOPMENTS  | 181             |
| TABLE 102 SIGNOSIS INC.: KEY PRODUCTS  | 182             |
| TABLE 103 SIEMENS HEALTHCARE DIAGNOSTICS: KEY PRODUCTS   | 183             |
| TABLE 104 SIEMENS HEALTHCARE DIAGNOSTICS: RECENT DEVELOPMENTS                                    | 183             |
| TABLE 105 SINGULEX, INC.: KEY PRODUCTS   | 184             |
| TABLE 106 SINGULEX, INC.: RECENT DEVELOPMENTS  | 185             |
| TABLE 107 THERMO FISHER SCIENTIFIC INC: KEY PRODUCTS   | 187             |
| TABLE 108 THERMO FISHER SCIENTIFIC INC: RECENT DEVELOPMENTS                                      | 187             |
| TABLE 109 WUXI APPTEC'S SERVICES   | 189             |

| <b>TABLE HEADING</b>                       | <b>PAGE NO.</b> |
|--|-----------------|
| TABLE 110 WUXI APPTEC: RECENT DEVELOPMENTS | 189             |
| TABLE 111 LIST OF PATENTS, 2006-2015       | 193             |

**LIST OF FIGURES**

| <b>FIGURE TITLE</b>   | <b>PAGE NO.</b> |
|---|-----------------|
| SUMMARY FIGURE GLOBAL CARDIAC BIOMARKER MARKET BY REGION, 2014-2020 (\$ MILLIONS)       | 8               |
| FIGURE 1 NUMBER OF PATENTS BY COUNTRY, IT* AND HEALTHCARE, 2013 (NO. OF PATENTS)        | 11              |
| FIGURE 2 NUMBER OF CARDIAC BIOMARKER PATENTS BY REGION*, 2011-2015 (NO. OF PATENTS)     | 13              |
| FIGURE 3 SHARES OF STAKEHOLDERS IN CARDIAC BIOMARKERS PATENTS, 2011-2015 (NO./%)        | 14              |
| FIGURE 4 NUMBER OF CARDIAC BIOMARKER PATENTS BY ASSIGNEE, 2011-2015 (NO. OF PATENTS)    | 15              |
| FIGURE 5 TOP STRATEGIES, 2011-2015 (NUMBER)   | 17              |
| FIGURE 6 GLOBAL DISTRIBUTION OF CARDIOVASCULAR DISEASE: DALY, 2004 (PER 100,000 PEOPLE) | 31              |
| FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE TRENDS, 2011-2018 (MILLION CASES)                | 32              |
| FIGURE 8 INTERPRETING ELEVATED LEVELS OF CARDIAC TROPONIN                               | 82              |
| FIGURE 9 RECENT KEY STRATEGIES OF CARDIAC BIOMARKER MARKET, 2011-2015 (NO./%)           | 106             |
| FIGURE 10 PARTNERSHIP AND COLLABORATION BY COMPANY,* 2011-2015 (NO./%)                  | 110             |
| FIGURE 11 PRODUCT APPROVALS AND PRODUCT CLEARANCES BY COMPANIES, 2011-2015 (NO./%)      | 112             |
| FIGURE 12 NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES BY COMPANY, 2011-2015 (NO./%)   | 115             |
| FIGURE 13 MERGERS AND ACQUISITIONS BY COMPANY, 2011-2015 (NO./%)                        | 117             |
| FIGURE 14 RECEIVER OPERATOR CHARACTERISTIC CURVES                                       | 126             |